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SHORT REPORT
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disease (pwMND) in Scotland
MARIA STAVROU1,2,3,4, JUDITH NEWTON1,2,3,4, GILL STOTT1, SHUNA
COLVILLE2,3,4, SIDDHARTHAN CHANDRAN1,2,3,4,5, SHARON ABRAHAMS2,3,4,
SUVANKAR PAL1,2,3,4,5 AND RICHARD DAVENPORT1,2,3,4,5
1Department of Clinical Neurosciences, NHS Lothian, Edinburgh, UK, 2Euan Macdonald Centre of MND
Research, Edinburgh, UK, 3Anne Rowling Regenerative Neurology Clinic, Edinburgh, UK, 4Centre of Clinical
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Abstract
Cognitive and behavioral abnormalities are recognized as an integral part of Motor Neurone Disease (MND) and occur
at all stages of the disease. The early detection of cognitive and behavioral symptoms in MND is critical. Such symptoms
are only reported when we explicitly ask, evaluate, document, and assess. In the National Institute for Health and Care
Excellence (NICE) MND guideline (2016), formal cognitive and behavioral assessment is incorporated in MND man-
agement and is fundamental to providing appropriate care to pwMND. Cognition is explicitly stated in 14 separate rec-
ommendations in the guidelines. The NICE guidelines therefore constitute pre-defined standards which we audited.
This audit highlights that health professionals increasingly recognize the significance of cognitive screening in MND and
follow more structured approaches in implementing this compared to previous years.
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Background
Cognitive and behavioral abnormalities are recog-
nized as part of Motor Neurone Disease (MND).
Approximately 15% of people with MND
(pwMND) fulfill diagnostic criteria for fronto-tem-
poral dementia (typically behavioral variant), while
milder changes in behavior and cognition affect a
further 35% of pwMND (1,2). Cognitive and
behavioral impairments have important functional
implications for pwMND and their families: they
increase caregiver burden, reduce survival, and
impact care planning (3). These impairments may
not be readily apparent at clinical interview, hence
the need to assess using standardized measures. In
the National Institute for Health and Care
Excellence (NICE) MND guideline (2016), cogni-
tive and behavioral assessment is incorporated in
MND management and is fundamental to provid-
ing appropriate care to pwMND (Table 1) (4,5,6).
The Edinburgh Cognitive and behavioral ALS
screen (ECAS) has been specifically developed and
validated (7,8). In Scotland, assessment of
pwMND is provided either via neuropsychology or
members of the multidisciplinary team (MDT),
usually the clinical nurse specialist. Furthermore,
Scotland benefits from an integrated national
healthcare team for MND closely aligned to the
Scottish MND register (relaunched in 2015 as
Clinical Audit Research and Evaluation of MND –
CARE-MND) (9). This is an electronic platform
for prospective, population-based research.
We conducted an audit to analyze “real-world”
experience of cognitive assessment in pwMND in
Scotland. Using the NICE guidelines, we meas-
ured whether we follow best practice.
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Objectives
To audit cognitive assessment in pwMND in
Scotland against two predetermined standards
by NICE:
 Following MND diagnosis, cognitive screening
is recommended in pwMND.
 Care planning should be adapted for people
with cognitive impairment and behav-
ior change.
Methods
During 2016, several educational activities
occurred within Scotland and the UK to encour-
age cognitive and behavioral screening of MND as
part of routine assessment. At the end of 2016, we
presented the preliminary results throughout
Scotland and identified obstacles to screening.
Data were captured from the CARE-MND
Register. Two time periods were audited:
1. January 2015 – December 2016
2. January 2017 – December 2017.
Results
(1) Between January 2015 and December 2016,
393 new cases were captured (Table 2). ECAS
was undertaken in 36% (n¼ 140). Almost 33%
(n¼131) did not have any form of cognitive
assessment. No data were recorded in the remain-
ing cases (31%; n¼ 122); this is likely attributed to
the following: there is no funded clinical
neuropsychology in some areas; long-term staff
sickness; in some regions, cognition was consid-
ered satisfactory and therefore cognitive screening
was not offered.
Total ECAS scores were available in 67%
(n¼ 94) and 50% had cognitive impairment
(defined by the cutoff total ECAS scores) (Figure
1(a)). There was a non-significant trend toward
fewer interventions (non-invasive ventilation, gas-
trostomy, riluzole) in cognitively impaired patients
(Figure 1(b)).
(2) In 2017, data were available from 193 inci-
dent cases (Table 2). Around 57% (n¼110)
underwent cognitive screening, with ECAS per-
formed in 86% (n¼95), and other forms of cogni-
tive assessments in the rest. Total ECAS scores
were available in 85% (n¼ 80); 54% of those had
cognitive impairment (Figure 1(a)). Comparing
those with and without cognitive impairment on
treatment, there was no statistically significant dif-
ference (Figure 1(b)).
Discussion
This audit highlights that health professionals
increasingly recognize the significance of cognitive
screening in MND and follow more structured
approaches compared to previous years. Cognitive
testing increased by 21% and ECAS was the most
commonly performed assessment. Of those
assessed, 56% were cognitively impaired, consist-
ent with previous population studies.
During the second cycle, cognitive assessments
were not recorded for 11.4%. The reasons include:
Table 1. Audit standards.
Standard 1. Following diagnosis of MND, cognitive screening is recommended in all patients.
The NICE recommendations are (4):
 At diagnosis, and if there is concern about cognition and behavior, explore any cognitive or behavioral changes with the person
and their family members and/or carers as appropriate. If needed, refer the person for a formal assessment in line with the NICE
guideline on dementia. [new 2016]
 The multidisciplinary team (MDT) should assess, manage and review the following areas, including the person's response to
treatment: … cognition and behaviour
 Tailor all discussions to the person’s needs, considering their communication ability, cognitive status and mental capacity
Standard 2. Care planning should be adapted for people with cognitive impairment and behavior change.
The NICE recommendations are:
1. Planning of end of life care
 Be sensitive about the timing of discussions and consider the person's current communication ability, cognitive status and
mental capacity
 Think about discussing advance care planning with people at an earlier opportunity if you expect their communication ability,
cognitive status, or mental capacity to get worse. Cognitive impairment and the number of reported behavioral features are
significantly related to advancing disease stage and are more likely to occur to those with cognitive changes at onset (5,6).
2. Use of gastrostomy
 Before a decision is made on the use of gastrostomy for a person with MND who has frontotemporal dementia, the neurologist
from the MDT should assess the following:
 The person's ability to make decisions and to give consent
 The severity of frontotemporal dementia and cognitive problems
 Whether the person is likely to accept and cope with treatment
3. Non-invasive ventilation
Before a decision is made on the use of non-invasive ventilation for a person with a diagnosis of frontotemporal dementia, the MDT
together with the respiratory ventilation service should carry out an assessment that includes: the person's capacity to make
decisions and to give consent, the severity of dementia and cognitive problems
(5) Crockford et al. Neurology 2018; (6) Elamin et al., Neurology 2013.
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(1) delay in data input in the CARE-MND plat-
form, (2) ECAS was not collected because it was
too soon after diagnosis. We offer pwMND follow-
up appointments with an MDT member 4–6
weeks post-diagnosis. This delay prevents miscon-
struing emotional overburdening with cogni-
tive impairment.
Regarding treatment, there was a non-
significant trend toward fewer interventions in cog-
nitively impaired patients and other groups have
also identified this (10). Those with cognitive
change or FTD may have difficulty coping with
NIV (11). Larger cohorts are required confirming
the association between interventions and cognitive
Table 2. Patient demographics.
Audit phase 1 Audit phase 2
Median age of onset 67 (Median Abs deviation ¼ 8) 66 (Median Abs deviation ¼ 8.5)
% males, % females 63%, 37% 61%, 39%
Median disease duration (in months) 27 (median Abs deviation ¼ 13) 25 (Median Abs deviation ¼ 13)
Figure 1. (a) Implementation of cognitive assessments Phase 1 & 2. In the UK, the cutoff for the ECAS total is 105. A score AT or
BELOW 105 suggests that a person may have cognitive impairment. “Pending” were the cases where ECAS was undertaken but the
data were not yet interpreted or inputted to the CARE-MND platform. (b) Interventions by cognitive status.
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impairment in MND. Specifically, more data are
needed on NIV compliance, the role of patients,
carers and physicians in the decision-making pro-
cess, and end-of-life practices in pwMND with
cognitive change. Our future work involves investi-
gating the profile of supportive/palliative interven-
tions in pwMND with mild or moderate cognitive
impairment, behavioral changes and the fronto-
temporal syndrome. Further studies should eluci-
date how to ensure appropriate interventions are
not inadvertently denied.
Additional pathways should be developed for
cognitive/behavioral screening for pwMND such
as: (1) Masterclasses/training days to enhance
health care professionals’ knowledge in ECAS; (2)
Establishment of dedicated ECAS clinics or incor-
porating psychologists into clinic; (3) Ongoing
support and access to neuropsychology services.
Neuropsychological intervention helps the MDT
manage the particularly complex cases.
Finally, the online register has contributed to
accurate and effective data capturing. CARE-
MND Platform is a national resource with an aver-
age case ascertainment coverage of 99% (7).
Centralizing data from across Scotland are unique
and beneficial for patient care. Ongoing multi-dis-
ciplinary collaboration is essential for mastering
data capture, attaining compliance with evidence-
based recommendations and continuing quality
improvement.
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